Overcoming the Multiple Scattering Limit in Optical Coherence Tomography
Project Number5R01EB031226-03
Former Number1R01EB031226-01
Contact PI/Project LeaderADIE, STEVEN GRAHAM
Awardee OrganizationCORNELL UNIVERSITY
Description
Abstract Text
Extending imaging depth is one of the grand challenges in optical microscopy, and many creative approaches
are under development to mitigate the detrimental impact of the phenomenon of ‘optical scattering’ and enable
deeper optical imaging in scattering media. Light propagating in dense tissue undergoes scattering events that
scramble the phase of the propagating optical wavefront, and thus disrupts the constructive interference needed
to focus/spatially localize the light to a diffraction-limited focal spot. Consequently, microscopic resolution is
typically only available in the so-called ‘single-scattering’ (SS) or ‘ballistic’ light regime. OCT is one of the leading
modalities in the field of deep microscopy, with maximum imaging depths typically 1–2 mm in scattering tissues.
However, the incredible success of OCT has in some ways led to lower motivation than in other optical imaging
fields to develop new approaches to address the problem of multiple scattering (MS). This is also a great
opportunity – by building upon its already deep imaging capabilities, OCT has the opportunity to once again be
at the forefront of research on pushing the imaging depth limits of optical microscopy. We propose an integrated
approach that combines (1) long-wavelength OCT (1700 nm window, lower scattering coefficient supporting
deeper imaging), (2) spectral-domain OCT (SD-OCT) in the conjugate imaging configuration to enhance the
deep OCT signal by 2-3 orders of magnitude relative to the standard imaging configuration, (3) hardware
adaptive optics (HAO) to correct tissue-induced aberrations and thereby boost the ballistic signal deep within
tissue, and (4) aberration-diverse OCT (AD-OCT) for suppressing MS. Our recently-developed AD-OCT
approach combines the advantages of a fiber-based OCT system with the principle behind the highly promising
coherent accumulation of single scattering (CASS) method. The CASS method coherently accumulates SS from
multiple illumination angles (plane wave illumination in full-field imaging geometry), whereas AD-OCT coherently
accumulates SS arising from illuminating the sample with different known aberration states, and leveraging
computational adaptive optics (CAO) to circumvent the resolution penalty normally associated with these
aberrations. Aim 1 will develop a method to overcome the aberration-diversity saturation limit, implement high-
speed GPU-based processing to address the Big Data problem in AD-OCT, and enable real-time feedback at
the time of imaging. Aim 2 will quantitatively compare the performance of Gaussian-beam OCT (with and without
HAO correction of tissue aberrations) vs. AD-OCT (with HAO correction of tissue aberrations). This will include
measurements of the depth-dependent 3D point-spread-function, which will also fill an important knowledge gap
in fundamental research on MS in OCT. Aim 3 will demonstrate AD-OCT beyond the current OCT multiple
scattering limit in human skin and mouse brain in vivo (we will ‘unlock’ the 2-5 mm depth range). If successful,
this proposal will demonstrate the deepest OCT imaging ever performed in human skin and mouse brain, and
so is significant from the perspective of fundamental imaging science and the biomedical applications of OCT.
Public Health Relevance Statement
NARRATIVE
The goal of this research program is to overcome the multiple scattering limit in optical coherence
tomography, and thereby address one of the grand challenges in the field of optical microscopy. We will
synergistically combine the advantages of a long-wavelength spectral-domain OCT system with adaptive optics,
and the principle behind the highly promising coherent accumulation of single scattering method. We propose to
demonstrate the deepest OCT imaging to date, in both human skin and mouse brain tissues, which is significant
from the perspective of both fundamental imaging science as well as the biomedical applications of OCT.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
872612445
UEI
G56PUALJ3KT5
CCV3WG2JG248
D4H1NV4APKP3
ELS2M3C6V2S5
EQA8NBEN9WD5
FFAZGE9NH3M8
K6JRCJJXFET1
M8FBSLHASMT3
P4LRVQT1H4K5
PJUVN8AT5416
RT1JPM9UMGM5
ZBMGUAZYFGC4
ZMP8BDLJTUW9
Project Start Date
05-June-2022
Project End Date
28-February-2026
Budget Start Date
01-March-2024
Budget End Date
28-February-2025
Project Funding Information for 2024
Total Funding
$358,198
Direct Costs
$218,414
Indirect Costs
$139,784
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$358,198
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01EB031226-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01EB031226-03
Patents
No Patents information available for 5R01EB031226-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01EB031226-03
Clinical Studies
No Clinical Studies information available for 5R01EB031226-03
News and More
Related News Releases
No news release information available for 5R01EB031226-03
History
No Historical information available for 5R01EB031226-03
Similar Projects
No Similar Projects information available for 5R01EB031226-03